- Conditions
- Squamous Cell Carcinoma of Head and Neck, Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Esophageal Cancer, Gastric Cancer, Melanoma, Renal Cell Carcinoma, Pancreatic Cancer, Cervical Cancer, Triple Negative Breast Cancer, Advanced Cancer, Metastatic Cancer
- Interventions
- Alomfilimab, Atezolizumab
- Drug
- Lead sponsor
- Kymab Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 222 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 6
- States / cities
- Duarte, California • New Haven, Connecticut • Orlando, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced May 22, 2026, 2:52 AM EDT